

LUPRON DEPOT

1.0 mg.

For Prostate Cancer

Date: Tuesday, May 30, 1995

To: Sales Force


From: Carrie Nutt

Re: 1995 AUA annual meeting

cc: Doug Durand
Don Patton
Alan MacKenzie
Karen Howard
Jim Salanty

Enclosed please find a copy of the follow-up letter sent to all AUA members announcing the results of the TAP & AUA Link-up to Guide the Grant. We recently received a letter from the AUA which thanked TAP for our generous support to both the AUA annual meeting and the other AUA continuing education projects.

I have also included the first of what we hope to be many newspaper articles featuring the results of the neoadjuvant studies presented at the AUA. There were over five abstracts presented at the annual meeting showing results similar to those seen in the multicenter study Dr. Soloway refers to in this article. We will keep you posted on further results from Dr. Soloway's research.



TAP 5053077



TAP HOLDINGS INC.
parent of TAP Pharmaceuticals Inc.

Bannockburn Lake Office Plaza
2355 Waukegan Rd
Deerfield, IL 60015


May 23, 1995

Arthur Turton, MD
182 Adams Road
Williamstown, MA 01267

Dear Dr. Turton,

TAP Pharmaceuticals Inc. proudly announces the outcome of the TAP & AUA Link-up to Guide the Grant at the recent meeting in Las Vegas. We would like to thank you for your support and participation which continues to be an integral part of our funding program. Over a thousand physicians cast ballots to allocate the \$100,000 grant to the five funds identified by the American Urological Association.

The results of the Guide the Grant balloting are as follows:



Expanding our commitment to urology and further enhancing our partnership with your specialty remains a major focus for TAP Pharmaceuticals.

We look forward to seeing you at the 1996 annual meeting in Orlando.

Sincerely,

Carrie Nutt
Urology Product Manager

TAP 5053078